| The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 23385859 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Treatment of advanced nonsmall cell lung cancer (NSCLC) has rapidly changed over the last decade. On the basis of the progress made in cancer biology, the old-fashioned 'one size fits all' chemotherapeutic approach is shifting to a novel approach in which treatment choice is mainly based on the tumor's biological genotype. The aim of the present review is to describe the anaplastic lymphoma kinase (ALK) translocation as a prominent molecular driver aberration in NSCLC, its prognostic and predictive role, and the new available treatment options. RECENT FINDINGS: Crizotinib is a tyrosine kinase inhibitor of MET, ALK and ROS1. Its impressive clinical activity shown in a phase IB trial led to accelerated approval for patients with ALK-positive advanced NSCLC. More recently, a phase III trial confirmed the high activity of crizotinib in this subset of lung tumors. Many new-generation ALK inhibitors are currently also in clinical development. SUMMARY: ALK-positive NSCLC has emerged as a distinct, well defined subset of lung malignancies. The use of ALK inhibitors deeply impacts the therapy of patients harboring such translocation. Nevertheless, to date, several issues remain open, such as the most suitable screening and diagnostic method for the detection of ALK gene rearrangement and expression and particularly the mechanisms of acquired resistance for further clinical development of these agents. |
| | |
Authors:
|
Manolo D'Arcangelo; Murry W Wynes; Fred R Hirsch |
Related Documents
:
|
23443559 - Lgals3bp regulates centriole biogenesis and centrosome hypertrophy in cancer cells. 21264469 - Symptomatic venous thromboembolism in asian colorectal cancer surgery patients. 20728239 - Expression and function of mirna in postoperative radiotherapy sensitive and resistant ... 20482489 - Targeting apoptotic signaling pathways in human lung cancer. 23013439 - Down-regulation of mir-101 in gastric cancer correlates with cox-2 overexpression and t... 21461569 - Myeloperoxidase g-463a polymorphism and risk of lung and prostate cancer in a turkish p... 2773949 - Industry-related urothelial carcinogens: application of a job-exposure matrix to census... 2789969 - Mortality among pulp and paper workers in berlin, new hampshire. 22685209 - Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenedi... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current opinion in oncology Volume: 25 ISSN: 1531-703X ISO Abbreviation: Curr Opin Oncol Publication Date: 2013 Mar |
Date Detail:
|
Created Date: 2013-02-06 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007265 Medline TA: Curr Opin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 121-9 Citation Subset: IM |
Affiliation:
|
aUniversity of Colorado Cancer Center, Aurora, Colorado, USA bIstituto Toscano Tumori, Civil Hospital, Livorno, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Activin, neutrophils, and inflammation: just coincidence?
Next Document: Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.